XML 26 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 9 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Cost Of Molecular Diagnostic Testing
Mar. 31, 2013
Cost Of Molecular Diagnostic Testing
Mar. 31, 2014
Cost Of Molecular Diagnostic Testing
Mar. 31, 2013
Cost Of Molecular Diagnostic Testing
Mar. 31, 2014
Research And Development Expense
Mar. 31, 2013
Research And Development Expense
Mar. 31, 2014
Research And Development Expense
Mar. 31, 2013
Research And Development Expense
Mar. 31, 2014
Selling, General, and Administrative Expenses
Mar. 31, 2013
Selling, General, and Administrative Expenses
Mar. 31, 2014
Selling, General, and Administrative Expenses
Mar. 31, 2013
Selling, General, and Administrative Expenses
Mar. 31, 2014
Crescendo
Cost Of Molecular Diagnostic Testing
Mar. 31, 2014
Crescendo
Cost Of Molecular Diagnostic Testing
Mar. 31, 2014
Crescendo
Research And Development Expense
Mar. 31, 2014
Crescendo
Research And Development Expense
Mar. 31, 2014
Crescendo
Selling, General, and Administrative Expenses
Mar. 31, 2014
Crescendo
Selling, General, and Administrative Expenses
Mar. 31, 2014
Options granted after December 5, 2012
Mar. 31, 2014
Options granted prior to December 5, 2012
Mar. 31, 2014
The 2010 Plan
Dec. 05, 2013
The 2010 Plan
Mar. 31, 2014
The 2010 Plan
Maximum
Mar. 31, 2014
2012 Purchase Plan
Mar. 31, 2013
2012 Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                                          
Number of shares approved                                                   3,500,000     2,000,000
Shares reserved for issuance exercise of options                                                 3,757,761     1,856,000  
Number of shares cancelled or expired without issuance     383,173                                           257,761        
Shares available for future grant                                                     5,509,201    
Service period of option vested, years     4 years                                                    
Options expire from date of grant, years                                             8 years 10 years          
Shares issued under the Plan                                                       144,000  
Options to purchase shares vested and exercisable, shares 7,823,794   7,823,794                                                    
Exercisable weighted average price of options $ 21.86   $ 21.86                                                    
Total unrecognized share-based compensation cost related to share-based awards granted $ 46,500,000   $ 46,500,000                                                    
Total unrecognized share-based compensation cost, weighted-average period, years     2 years 5 months 27 days                                                    
Total share-based compensation expense $ 13,640,000 $ 6,731,000 $ 27,432,000 $ 20,435,000 $ 207,000 $ 252,000 $ 639,000 $ 811,000 $ 3,042,000 $ 818,000 $ 4,670,000 $ 2,496,000 $ 10,316,000 $ 5,607,000 $ 21,911,000 $ 16,969,000 $ 200,000 $ 200,000 $ 2,000,000 $ 2,000,000 $ 4,700,000 $ 4,700,000